Compare Sibanye Stillwater Ltd (SBSW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs BIO-TECHNE Corp — how do they compare? Sibanye Stillwater Ltd trades at $13.14 (market cap $9.35B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Sibanye Stillwater Ltd pays the higher dividend (6.27%). Which is the better fit depends on your goals.
| SBSW | TECH | |
|---|---|---|
Market Cap | $9.35B | $11.34B |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $72.48 |
52-Week Low | $8.00 | $43.31 |
Enterprise Value | $10.29B | $11.36B |
Dividend Yield | 6.27% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $12.90, up 0.86% today, with a bullish technical signal from moving averages and ADX indicators. Recent Q2 2026 earnings beat expectations with EPS of $1.34 versus $1.26, and the company reported a strong turnaround in operating cash flow to $21.41 billion in 2025. Valuation ratios appear attractive with a P/E of 10.2 and EV/EBITDA of 5.2, while analyst consensus is a Buy with a $14.00 price target.
The outlook is positive due to robust earnings performance and improving cash flows, but risks include volatile commodity prices and high debt levels. Investment opportunity lies in potential upside to the consensus target, supported by operational momentum and disciplined capital allocation plans highlighted in recent news.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
